-
Could the Zika virus be used to treat glioblastomas?
The University of Cambridge is to begins trials using the Zika virus on glioblastoma, the most common and aggressive form of brain tumour. Glioblastomas affect 2,200 people in the UK each year
-
New insight into medulloblastoma
The most common type of malignant childhood brain cancer has been identified as seven separate conditions each needing a different treatment, new research has revealed.
-
Announcing our new patient-led data bank initiative
We are launching a global, patient-led data bank, which will allow patients to unite in sharing their data, helping them to make better informed decisions about their own treatment plans, as well as helping vital research that could bring us closer to finding a cure.
-
We are co-funding Marie Curie’s call to address gaps in palliative and end of life care research
The terminal illness charity is looking for applications that address its key research priorities identified by carers, health and social care professionals and people with terminal illness, and particularly, those areas that have until now received the least attention
-
University fashion show raises £28,000
St Andrew’s Fashion Show (FS) has raised over £28,000 for The Brain Tumour Charity in a bid to fund research in to vital treatments to tackle the disease.
-
Benefit cut equals further hurt for the bereaved
Why a decision to cut benefits paid to bereaved parents is not in the interests of affected families.
-
UK research into the use of cannabidiol to treat brain tumours
Researchers from the Nottingham University’s children’s brain tumour centre are now looking into the effects of cannabidiol (CBD), the non-psychoactive ingredient in marijuana
-
Team Ipreo take on Tough Mudder
An energetic team from global financial services technology company Ipreo will soon be taking on the gruelling Tough Mudder in support of The Brain Tumour Charity.
-
United in the call for brain tumour one-year survival targets to be met
The Brain Tumour Charity CEO, Sarah Lindsell, has co-signed a letter to NHS organisations urging them to meet their one-year survival targets for the early diagnosis of brain tumours.
-
As a snap general election is called, our battle continues
While Theresa May admits division in Westminster, our Chief Executive Sarah Lindsell says we must stand together stronger than ever to defeat brain tumours.
-
A neurosurgeon’s view
Trainee neurosurgeon at University Hospital Coventry and Warwickshire, Yasir Chowdhury, shines a light on day-to-day life in one of the most complex and dangerous areas of surgery and shares his hopes for finding a cure for brain tumours
-
How we’re fighting for people affected by brain tumours
From establishing a new cancer taskforce to ensuring benefits reviews take brain tumour patients into account, read our roundup of key activities from the past few weeks.
-
Immunotherapy drug shows lack of promise in Phase 3 clinical trial for glioblastoma patients
Last week Bristol-Myers Squibb announced the initial results from their Phase 3 clinical trial that was assessing the effectiveness and safety of the immunotherapy drug Nivolumab in patients with recurrent glioblastoma.
-
A new, non-disruptive brain surgery technology is now being used in London
BrainPath is a surgical technique that uses the brain’s own tissue folds to tract a path to the tumour site. It is designed to be minimally invasive.
-
We know mental health can affect those living with a brain tumour, but are we doing enough?
Ally Rooney posts an open letter to doctors, nurses, and allied health professionals who care for people with a brain tumour.
-
How has DevoManc affected The Brain Tumour Charity?
Last year, Greater Manchester became the first English region to gain control of health spending. Read our view on the impact this has had on charities.
-
Encouraging results for new clinical approach to glioblastoma treatments
Researchers at McGill University Health Centre (MUHC), Montreal have developed a new clinical approach to enhance the efficiency of treatment for glioblastomas, which increased the average survival time to 22 months.
-
Glasgow’s £32m Imaging Centre of Excellence has now opened
The Imaging Centre of Excellence (ICE), was opened last Wednesday at the University of Glasgow, with the aim to be a global hub for precision medicine.
-
Diageo dinner in memory of much-loved colleague
Diageo chose to support The Brain Tumour Charity following the sudden death of much loved colleague Mark Richardson.
-
Gene-editing techniques give new insight on key protein involved in medulloblastoma development
Researchers at St. Jude Children’s Research Hospital, USA have revealed how a key protein involved in driving the growth of the most aggressive form of medulloblastoma also plays a role in stopping its development.
-
Pioneering research reveals new genetic errors that lead to an inherited risk of developing glioma
Scientists from The Institute of Cancer Research (ICR) have discovered 13 new genetic errors related with an increased risk of developing glioma in one of the largest ever studies of this devastating disease
-
Our work with House of Lords Select Committee on Charities
On Sunday 26 March, the House of Lords Select Committee on Charities published a report, ‘Stronger charities for a stronger society’, following an inquiry into issues facing the charity sector in England and Wales.
-
New research uncovers a molecule that halts DIPG tumour growth
A team of researchers from Northwestern University, USA have identified a molecule that could be used to inhibit the growth of the most fatal paediatric brain tumour, diffuse pontine intrinsic glioma (DIPG).
-
Delivering equal access to benefits for brain tumour patients
Over the last three years, The Brain Tumour Charity has expressed concerns about the assessment criteria used for Personal Independence Payments (PIPs), and their impact on people affected by a brain tumour.